Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Arzerra
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Rituximab in paediatric onset multiple sclerosis: a case series.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Change in the clinical development program for laquinimod
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Power estimation for non-standardized multisite studies.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
TGN1412: From Discovery to Disaster.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Spin-offs: Meet the structure specialists

Pages